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Abstract
The functional role of bone morphogenetic protein (BMP) signalling in colorectal cancer (CRC) is poorly defined,
with contradictory results in cancer cell line models reflecting the inherent difficulties of assessing a signalling
pathway that is context-dependent and subject to genetic constraints. By assessing the transcriptional response of
a diploid human colonic epithelial cell line to BMP ligand stimulation, we generated a prognostic BMP signalling
signature, which was applied to multiple CRC datasets to investigate BMP heterogeneity across CRC molecular
subtypes. We linked BMP and Notch signalling pathway activity and function in human colonic epithelial cells,
and normal and neoplastic tissue. BMP induced Notch through a -secretase-independent interaction, regulated by
the SMAD proteins. In homeostasis, BMP/Notch co-localization was restricted to cells at the top of the intestinal
crypt, with more widespread interaction in some human CRC samples. BMP signalling was downregulated in the
majority of CRCs, but was conserved specifically in mesenchymal-subtype tumours, where it interacts with Notch
to induce an epithelial–mesenchymal transition (EMT) phenotype. In intestinal homeostasis, BMP–Notch pathway
crosstalk is restricted to differentiating cells through stringent pathway segregation. Conserved BMP activity and
loss of signalling stringency in mesenchymal-subtype tumours promotes a synergistic BMP–Notch interaction,
and this correlates with poor patient prognosis. BMP signalling heterogeneity across CRC subtypes and cell lines
can account for previous experimental contradictions. Crosstalk between the BMP and Notch pathways will render
mesenchymal-subtype CRC insensitive to -secretase inhibition unless BMP activation is concomitantly addressed.
© 2017 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
Keywords: BMP; Notch; EMT; colorectal cancer subtypes
Received 31 August 2016; Revised 30 January 2017; Accepted 20 February 2017
No conflicts of interest were declared.
Introduction
In adult tissue homeostasis, stringent control of stem cell
division and daughter cell fate determination is achieved
by interactions of various signalling pathways. These
signalling cascades consist of secreted ligands (mor-
phogens), receptors and antagonists, with overlapping
expression of pathway constituents allowing synergistic
or antagonistic interactions. It is the complexity of
these intracellular networks, amplifying or attenuating
© 2017 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
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the biological effects of individual pathways in a
context-dependent fashion, that generates a powerful
mechanism for conferring diverse cellular functions
on various tissues [1]. The intestinal epithelium, with
its stereotypical architecture, is a paradigm for mor-
phogenic cell fate control, as it undergoes continual
replacement supported by intestinal stem cells at the
base of the intestinal crypt. Daughter cells, generated by
asymmetrical stem cell division, pass along the vertical
axis of the intestine, proliferate in the transit-amplifying
zone, and then mature and undergo terminal differ-
entiation as they approach the luminal surface. The
epithelial cell response to morphogens is determined
by position along the crypt–villus axis as cells migrate
through intercompartmental Wnt, Hedgehog, bone
morphogenetic protein (BMP) and Notch morphogen
gradients [2].
BMPs are members of the transforming growth fac-
tor (TGF)-β superfamily. Secreted BMP ligands bind
and activate cell surface BMPR1A (ALK3), BMPR1B
(ALK6) and BMPRII receptors, with signal transduction
being achieved by C-terminal phosphorylation of the
Mothers against decapentaplegic, Drosophila (SMAD)
1, 5 and 8 proteins. Activated p-SMAD1/5/8 com-
plexes with SMAD4, translocates to the nucleus, and
induces expression of target genes such as Inhibitor
of DNA binding (ID) to initiate anti-proliferative and
pro-differentiation transcription programmes [2]. The
four mammalian Notch genes encode transmembrane
receptors that are activated by neighbouring cell sur-
face ligands from the Jagged and Delta-like families.
Ligand–receptor binding renders the intracellular sub-
unit of the receptor susceptible to proteolytic cleavage
by γ-secretase, releasing the Notch intracellular domain
(NICD) into the cytosol. Translocation of cleaved NICD
in the nucleus derepresses and activates the expression
of Hairy and enhancer of Split1 related (HES and HEY)
target genes by binding to the transcription factor CSL
and the co-activator Mastermind-like 1. Lateral inhi-
bition between Notch-activated and neighbouring cells
mediates binary cell fate decisions, and, in the intestine,
this pathway is important for regulating secretory versus
enterocyte differentiation programmes in the upper part
of the crypt. Murine models have also shown that crypt
base Notch signalling promotes progenitor cell prolifer-
ation, implicating Notch as a key pleiotropic signalling
pathway with a variable effect on intestinal cell function,
depending on cell position [3].
Consistent with its role in intestinal homeostasis, dys-
regulation of BMP signalling can promote intestinal
tumourigenesis, with highly penetrant germline muta-
tions in the BMP pathway being responsible for juvenile
polyposis syndrome [4,5] and hereditary mixed polypo-
sis syndrome [6].
Furthermore, genetic variation in the BMP pathway
is an important determinant of sporadic colorectal can-
cer (CRC) risk, with predisposing single-nucleotide
polymorphisms having identified at ligand, antagonist
and intracellular effector levels of the pathway [7].
Despite this, the precise role of BMP signalling in
intestinal neoplasia is poorly defined. Some studies
have demonstrated increased expression of BMP ligands
as lesions progress through the adenoma–carcinoma
sequence [8,9], whereas others have reported inactiva-
tion of the pathway at the cancer transition stage [10,11].
In vitro results from cancer cell lines are contrasting,
with BMP signalling inducing cytostasis and differen-
tiation [12,13] or, alternatively, promoting cell motil-
ity, invasiveness [8,14], epithelial–mesenchymal transi-
tion (EMT) [15,16] and increased tumour volume [17]
in different experimental contexts. Subsequent work
has shown considerable genetic constraints on pathway
activity, with variable effects of BMP signalling accord-
ing to the underlying SMAD4 and p53 mutation status
of the cancer cell lines used [18,19]. Cumulatively, this
work highlights the inherent difficulties in assessing sig-
nalling pathway activity in cancer cells. The functional
effects of BMP signalling are dependent on endogenous
pathway constituent expression, the activity of interact-
ing morphogens, genetic constraints, and cellular con-
text, all of which may differ in cancer cell populations.
Recent molecular stratification and analysis by the
Colorectal Cancer Subtyping Consortium has revealed
considerable disease heterogeneity, and defined four
distinct CRC subtypes [consensus molecular subtypes
(CMSs) 1–4], each with a unique pathogenic molec-
ular pathway, and with variable responses to treat-
ment and prognosis. CMS1 [microsatellite instability
(MSI)] is characterized by hypermutation, MSI, and
strong immune system activation (14% of cases). CMS2
(canonical) is driven by Wnt pathway activation, clas-
sically through adenomatous polyposis coli mutation
(37%). CMS3 (metabolic) is characterized by metabolic
dysregulation (13%). CMS4 (mesenchymal) tumours
have TGF-β activation and stromal invasion, and carry
the worst prognosis of all of the subtypes (23%). A fur-
ther 13% of cases are indeterminate [20].
As the functional effect of the BMP pathway is con-
textually dependent, we wished to investigate whether
the activity of this critical homeostatic pathway varies
according to CRC molecular subtype. To investigate
this, we assessed the transcriptional response of an
immortalized human colonic epithelial cell (HCEC)
line, derived from a normal crypt explant [21], to recom-
binant BMP ligand stimulation. From this, we generated
a BMP gene signature, which we assessed in multiple
CRC datasets. Here, we show that BMP signalling inter-
acts with intracellular Notch signalling to promote an
EMT phenotype in intestinal epithelial cells, and that
this interaction is relevant in clinically aggressive CRC
subtypes.
Materials and methods
Ethics
Ethical approval for the use of archival tissue was
provided by the South-West Hampshire Research Ethics
Committee A (REC 06/Q1702/99), and that for for
© 2017 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2017; 242: 178–192
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endoscopic samples was provided by Oxfordshire
Research Ethics Committee A (REC 10/H0604/72).
Informed consent was obtained from all patients.
Cell culture and analysis
HCECs were cultured as described by Roig et al [21].
HCECs were subjected to treatment with recombinant
proteins and signalling pathway inhibitors, and small
interfering RNA (siRNA)-mediated gene knockdown,
andwere used in chromatin immunoprecipitation (ChIP)
[22] and cell migration experiments as described in
supplementary material, Supplementary materials and
methods. The primers used in ChIP experiments are
listed in supplementary material, Table S1.
Human tissue sections
Formalin-fixed, paraffin-embedded sections (4 μm)
were de-waxed in xylene and rehydrated through
graded alcohols to water. De-waxed sections were sub-
jected to immunohistochemical and in situ analysis [23]
as described in supplementary material, Supplementary
materials and methods.
Immunofluorescence
Cultured cells were protected from the light, fixed,
washed, and incubated with primary antibodies, as
described in supplementary material, Supplementary
materials and methods.
Isolation of individual human colonic crypts
Colonic biopsies from three different patients were
washed with phosphate-buffered saline and incubated
in 5ml of dissociation medium [30mM EDTA in Dul-
becco’s modified Eagle’s medium without Ca2+ and
Mg2+, 0.5mM dithiothreitol, and 2% RNAlater (Life
Technologies)] for 10min at room temperature. Tissue
was shaken vigorously for 30 s to release individual
crypts. Ten single crypts from each patient were hemi-
sected with fine needles under a dissecting microscope,
and individual hemicrypts were then aspirated. RNA
was extracted, preamplified with the TaqMan PreAmp
kit (Applied Biosystems), and reverse transcribed prior
to quantitative polymerase chain reaction (PCR).
Gene expression arrays
For gene expression profiling, we used three controls
and three experimental groups for each time point (4
and 24 h). Samples were profiled by the use of Illu-
mina gene expression arrays (Human-HT-12v4 expres-
sion BeadChip). Details of data processing are described
in supplementarymaterial, Supplementarymaterials and
methods.
Gene set enrichment analysis (GSEA)
GSEA was performed as described by Lin et al [24] and
in supplementarymaterial, Supplementarymaterials and
methods. A list of genes used in the enrichment analysis
is given in supplementary material, Table 6B1 [25–28].
Kaplan–Meier survival analysis
K-means clustering was used to identify two patient
groups with similar gene expression levels by use of the
‘k-means’ function from the Statistics Toolbox in MAT-
LAB. Kaplan–Meier survival curves were generated by
use of a MATLAB script, and P values were computed
with a log-rank test.
Human CRC patient cohorts
RNA-sequencing data from sporadic CRC patients
was downloaded from The Cancer Genome Atlas
(TCGA) data portal (https://cancergenome.nih.gov) and
RSEM-normalized as distributed by TCGA. Tumour
samples were matched to published CRC subtypes
[20,29,30]. If, for any given patient, multiple sam-
ples were profiled, we randomly selected one sample
for further analysis. ANOVA was used to compare the
mean expression values of BMP4, BMP2, BMPR1A,
BMPR1B, BMPRII, SMAD1, SMAD4 and SMAD5
across subtypes.
Results
Global transcriptional profiling of BMP2/4-treated
HCECs reveals overlapping target gene expression
Previous studies have shown variable expression levels
of BMP2 and BMP4 in CRC [8]. In order to determine
the downstream effectors of these ligands in intestinal
epithelium, we treated diploid, immortalized HCECs
with recombinant human BMP2 or BMP4, and assessed
global gene expression changes by microarray analysis
at 4 and 24 h post-treatment, to capture both early and
secondary changes in expression (supplementary mate-
rial, Table S2). Using a fold-change of>2 and a false dis-
covery rate (FDR) of <0.05, we identified 99 (67 upreg-
ulated and 32 downregulated) differentially expressed
genes (DEGs) induced by BMP2 and 87 (51 upregulated
and 36 downregulated) DEGs whose differential expres-
sion was caused by BMP4 at 4 h post-treatment (sup-
plementary material, Tables S3–S5). Using the same
cut-off criteria, we identified 528 (279 upregulated
and 249 downregulated) DEGs induced by BMP2 and
510 (281 upregulated and 229 downregulated) DEGs
whose differential expression was caused by BMP4
at 24 h post-treatment as compared with vehicle-only
treated cells (Figure 1A; supplementary material, Tables
S3–S5). We observed 82% and 84% overlap between
BMP2-induced and BMP4-induced target genes at 4
and 24 h respectively, implying functional redundancy
between these ligands (Figure 1B; supplementary mate-
rial, Table S5). Extending our search to identify biologi-
cal processes affected by BMP2 or BMP4, we computed
enrichment scores [31] for curated gene sets available in
© 2017 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2017; 242: 178–192
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the C2 database [32], and found a statistically significant
overlap in the number of downstream pathways affected
by these two effectors of BMP signalling (Figure 1C;
supplementary material, Table S6A).
Next, we interrogated global expression profiling
data from BMP-treated cells by using GSEA signatures
specifically associated with colonic epithelial home-
ostasis and tumourigenesis (supplementary material,
Table S6B1). Consistent with the putative homeostatic
role of BMP signalling in the differentiating cells of
the intestinal epithelium, we saw marked downregu-
lation of genes associated with proliferation [BMP2
at 4 h, normalized enrichment score (NES)= –7.92,
p< 0.001; BMP4 at 4 h, NES= –8.82, p< 0.001;
BMP2 at 24 h, NES= –3.69, p= 0.002; BMP4 at 24 h,
NES= –2.39, p= 0.028; supplementary material, Table
S6B2]. We also noted statistically significant positive
enrichment of gene signatures characterizing active
Notch signalling (BMP2 at 4 h, NES= 4.37, p< 0.001;
BMP4 at 4 h, NES= 3.94, p< 0.001; BMP2 at 24 h,
NES= 2.46, p= 0.027; BMP4 at 24 h, NES= 2.74,
p= 0.011; Figure 1D; supplementary material, Table
S6B3) and EMT (BMP2 at 4 h, NES= 3.17, p= 0.003;
BMP4 at 4 h, NES= 3.04, p= 0.002; BMP2 at 24 h,
NES= 2.62, p= 0.011; BMP4 at 24 h, NES= 3.06,
p= 0.002; Figure 1D; supplementary material, Table
S6B4). Apoptosis and senescence were not significantly
affected by BMP stimulation of immortalized HCECs
(supplementary material, Table S6B5).
BMP–Notch crosstalk in HCECs occurs through a
TGF-β-independent mechanism and is differentially
regulated by SMAD1 and SMAD5
Given the enrichment of Notch signalling in response
to BMP stimulation, we investigated the mechanism
of BMP–Notch crosstalk in HCECs. At 1 μM, the
selective BMP type 1 receptor inhibitor K02288 abol-
ished recombinant BMP4 ligand induction of both BMP
and Notch target genes, with dose-dependent inhibition
being seen at lower concentrations. In contrast, low con-
centrations (10–30 nM) of the specific ALK2/3 inhibitor
LDN193189 effectively abrogated Notch target gene
expression following BMP ligand stimulation. Given
the selectivity of LDN193189 for BMP inhibition over
TGF-β or activin signalling, these results indicate that
Notch signalling is downstream of receptor-mediated
activation of the BMP pathway rather than involv-
ing cross-activation of TGF-β or activin pathways [33]
(Figure 2A; supplementary material, Figure S1). Sim-
ilar results were obtained with BMP2 treatment (data
not shown). Induction of HES1 expression by BMP4
was partially abrogated by inhibition with the canoni-
cal Notch pathway γ-secretase inhibitor (GSI), diben-
zazepine (Figure 2A), whereas HEY1 expression was
unaffected. In contrast, γ-secretase inhibition abolished
HES1 expression following Notch ligand (JAG1) stim-
ulation (Figure 2B), indicating that BMP can acti-
vate Notch signalling through a γ-secretase-independent
pathway. Interestingly, the combination of exogenous
BMP4 and JAG1 stimulation had a synergistic effect on
HES1 upregulation, indicating that the biological effects
of Notch activation could be amplified by the intracellu-
lar interaction between the BMP and Notch pathways
(Figure 2B). To look for direct interactions between the
BMP and Notch intracellular signalling pathways, we
used ChIP with an anti-SMAD1/5 antibody to pull down
chromatin from BMP4-treated HCECs. Enrichment for
predicted regions of chromatin in the promoters ofHEY1
and NOTCH1 indicated SMAD1/5 DNA binding. No
strong evidence for SMAD binding was seen at our pre-
dicted binding sites in the HES1 promoter; however, it
is possible that binding occurs at upstream or down-
stream regions (supplementary material, Figure S1B).
Together these data demonstrate an intracellular inter-
action between activated BMP signalling and the Notch
pathway.
TGF-β is known to activate Notch signalling [34],
so, to exclude the effect of TGF-β signalling as a
potential intermediate pathway in this investigation, we
assessed the effect of recombinant TGF-β3 ligand stim-
ulation on HCECs. TGF-β activation had no effect on
HES1 expression but did upregulateHEY1, an effect that
could be abrogated by co-incubation with the TGF-β
receptor-specific inhibitor SB431542. TGF-β receptor
inhibition had no significant effect on the activation of
Notch target genes following BMP ligand stimulation,
indicating that the crosstalk between the BMP andNotch
pathways was not mediated through TGF-β signalling
(Figure 2C).
Next, we used siRNA to knock down BMP pathway
constituents, to determine whether this affected down-
stream Notch activation. SMAD5 knockdown (>50%
knockdown; supplementary material, Figure S1E) sup-
pressed BMP4 ligand activation of both HES1 and
HEY1, whereas SMAD1 knockdown (>70% knock-
down; supplementary material, Figure S1E) had no
effect on HEY1 expression and, surprisingly, markedly
increased the HES1 response to BMP4 ligand stimula-
tion. The effect of combined simultaneous knockdown
of SMAD1 and SMAD5 was similar to that seen with
SMAD5 knockdown alone. These results indicate that
Notch target gene expression is variably regulated by
SMAD proteins, with intact SMAD1 suppressing, and
SMAD5 amplifying,HES1 expression, following BMP4
stimulation; however, SMAD5 is the dominant media-
tor in determining theHES1 response to BMP activation
(Figure 2D).
BMP and Notch signalling are partially segregated
in normal colonic crypts but co-localize in some
human cancers
Next, to ensure that BMP/Notch co-expression and inter-
action was not a human cell line artefact, we extracted
and hemisected individual normal human colonic crypts
(30 from three patients) to assess the physiological
expression of BMP and Notch pathway constituents and
target genes. There was significantly higher expression
of most BMP and Notch target genes in the top halves
© 2017 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2017; 242: 178–192
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Figure 1. Global transcriptional profiling of BMP2/4-treated HCECs. (A) Venn diagram showing overlapping and uniquely DEGs (fold change
of >2, FDR of <0.05) between BMP2-treated or BMP4-treated as compared with untreated HCECs at 4 h or 24 h post-stimulation. (B) Heat
map visualization of changes in genes significantly regulated by at least one treatment (BMP2 or BMP4) after 4 or 24 h. (C) Heat map
showing upregulated pathways from the MSigDB-C2 database (Broad Institute) that were significant in at least one condition following
BMP2 or BMP4 treatment of HCECs. (D–F) GSEA in BMP4-treated versus untreated HCECs using a priori gene sets for cell proliferation (D),
Notch signalling (E) and EMT (F) signatures (supplementary material, Table S6B1–S6B4).
© 2017 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2017; 242: 178–192
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Figure 2. BMP4 induction of Notch target genes is independent of canonical Notch signalling and is regulated by SMAD proteins. (A)
Relative HES1 and HEY1 mRNA levels in HCECs 24 h after control vehicle or BMP4 treatment with or without two different BMP inhibitors
at three different concentrations (K02288 and LDN193189 at 10 nM, 30 nM and 1 μM) and two concentrations of the GSI dibenzazepine (1 nM
and 1 μM). (B) Relative HES1 mRNA levels in HCECs 24 h after control vehicle, JAG1 and/or BMP4 stimulation, with or without γ-secretase
inhibition with 1 μM dibenzazepine. (C) Relative HES1 and HEY1 mRNA levels in HCECs 24 h after control vehicle, TGF-β3 or BMP4 ligand
stimulation, with or without the specific TGF-β inhibitor SB431542. (Di) Relative HES1 and HEY1 mRNA levels in HCECs after SMAD1 or
SMAD5 knockdown (KD) or simultaneous SMAD1 and SMAD5 KD) for 48 h followed by vehicle-only control or BMP4 stimulation for 24 h.
All values are mean± standard error of the mean (n= 2). Differences in fold change in gene expression in KD cells are the consequence of
increased cell density resulting from additional culture time in these experiments. (Dii) Western blot showing increased expression of HES1
in response to BMP4 (200 ng/ml) stimulation, and abrogation of this response following SMAD5 knockdown.
© 2017 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2017; 242: 178–192
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of colonic crypts, although HES1 expression was more
evenly spread across the crypt (Figure 3A). In situ
hybridization for ID1 and immunohistochemistry for
HES1 and Ki67 on serial sections of human colonic
crypts (54 well-orientated crypts analysed from four
paraffin blocks) showed co-localization of pathway tar-
get genes in the cell population at the top of the crypt,
with only HES1 expression being seen in the dividing
cells of the stem/progenitor zone (Figure 3B). Interest-
ingly, the mRNA expression of the ligands and recep-
tors of both pathways did not always mirror target
gene activity, indicating the importance of mechanisms
other than simple ligand–receptor interaction for reg-
ulating and segregating morphogen pathway activity
(Figure 3A). These data indicate that, in the normal
intestinal crypt, stringent control of morphogen sig-
nalling gradients partially segregates these pathways,
with restricted co-localization in the differentiating cell
population and no evidence of shared expression in the
stem/progenitor zone at the crypt base.
Next, we used ID1 mRNA in situ hybridization
and HES1 immunohistochemistry on serial sections
from colorectal tumour tissue to assess whether loss
of stringency in CRC resulted in more widespread
co-localization of these pathways. We saw consider-
able variability in ID1 expression in human colorectal
lesions, with positive staining in the malignant epithe-
lium of 24% (25/105) of tumours, consistent with the
known frequency of mesenchymal tumours (Figure 3C,
cancer 1). Negligible ID1 signals were seen in other
samples (Figure 3C, cancer 2). Co-localization of ID1
and HES1 staining was seen in 76% (19/25) of the
ID1-positive samples (Figure 3C). BMP signalling prin-
cipally acts upon the intestinal epithelial cell popu-
lation [2]. Consistent with this, we saw little or no
ID1, p-SMAD5 or HES1 expression in the stroma sur-
rounding normal colonic crypts or CRCs (supplemen-
tary material, Figure S2A).
The BMP signalling pathway activity is variable
across different tumour subtypes
Given the variable expression of mRNA of the BMP
target gene ID1 in the epithelium of different human
CRCs, we assessed the mRNA expression levels of
BMP signalling components in CRC subtypes by using
TCGA RNA-sequencing data [35]. We saw differential
expression of BMP2 and BMP4 ligands in all tumour
subtypes, with downregulation of BMP2 and upregu-
lation of BMP4 expression as compared with normal
colon (Figure 4A). In intestinal homeostasis, BMP2
is expressed by both the mesenchyme and epithelium,
whereas BMP4 is predominantly stromal in origin.
We used isotopic in situ hybridization to show that the
differential BMP2/4 expression change identified in the
TCGA dataset is predominantly the consequence of
loss of normal BMP2 expression and gain of aberrant
BMP4 expression in dysplastic intestinal epithelium
(Figure 4A). BMPR1A expression was globally reduced
across all CRC subtypes, but BMPRII expression was
retained and BMPR1B expression was upregulated
specifically in mesenchymal tumours (Figure 4B).
Similarly, there was considerable variability in the
expression of the SMAD genes. Reduced SMAD1 and
SMAD4 expression was seen across all cancer sub-
types, but SMAD5 was differentially expressed: it was
downregulated in canonical tumours (n= 149), but was
retained and modestly upregulated in poor-prognosis,
mesenchymal tumours (n= 78) (Figure 4C). Immuno-
histochemistry confirmed variable epithelial expression
of p-SMAD5 in the malignant epithelium of different
CRCs (supplementary material, Figure S2B). More-
over, we found that SMAD5 expression levels had
independent prognostic value in stratifying patients
with Stage 3 and 4 CRC into high-risk and low-risk
groups (p= 0.046; supplementary material, Figure 2C).
As BMP4 appears to be the active ligand in CRC,
we used our BMP4 transcriptional profiling data to
generate a ‘BMP signature’ consisting of 281 genes
with fold changes of >2 and FDRs of <0.05 in HCECs
(supplementary material, Table S5B). We used this
signature to investigate active BMP signalling activity
across the different molecular subtypes of CRC in
multiple publically available datasets. Using GSEA
on TCGA RNA-sequencing data, we found profound
downregulation of BMP signalling in canonical tumours
(n= 149, NES= –3.49, p= 0.001) as compared with
normal colonic tissue (n= 41). Similarly, MSI tumours
showed negative enrichment (n= 110, NES= –3.23,
p= 0.002), but this trend was shifted towards upregu-
lation of the BMP signature in mesenchymal tumours
(n= 78, NES= 1.79, p= 0.065) (Figure 4D). Two inde-
pendent datasets confirmed the BMP signature to be
upregulated in the mesenchymal subtype as compared
with the canonical subtype (Academic Medical Centre
AJCC, NES= 4.26, p< 0.001; Melbourne–Moffitt,
NES= 3.15, p= 0.003; Figure 4E) and MSI subtype
(AJCC, NES= 4.10, p< 0.001; Melbourne–Moffitt,
NES= 8.033, p< 0.001; supplementary material,
Figure S2D). A panel of CRC cell lines classified into
the CMS categories (canonical, n= 38; MSI, n= 14;
and mesenchymal, n= 26) showed similar differen-
tial BMP signalling between mesenchymal tumours
and other subtypes (mesenchymal versus canonical,
NES= 8.34, p< 0.001; mesenchymal versus MSI,
NES= 12.54, p< 0.001) (Figure 4E; supplementary
material, Figure S2D).
BMP–Notch crosstalk acts through SNAI1
to promote an EMT phenotype
BMP ligand stimulation of HCECs caused enrichment
of genes associated with Notch signalling and EMT
(Figure 1D). Notch signalling induces EMT [36],
and together these pathways are associated with poor
prognosis in patients with CRCs [37]. We used GSEA
analysis on the TCGA dataset to confirm that Notch and
EMT gene signature enrichment mirrored the variable
activation of our BMP signalling signature in CRC
subtypes, with statistically significant upregulation in
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on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org www.thejournalofpathology.com
BMP and Notch interaction in CRC subtypes 185
Figure 3. BMP and Notch signalling are partially segregated in normal colonic crypts but co-localize in some human CRCs. (A) Relative mRNA
expression levels of BMP and Notch pathway ligands, receptors and target genes in the bottom versus the top of hemisected individual
normal human colonic crypts (n= 30, three patients). (B) Serial sections of normal human colonic tissue stained with Ki67-specific and
HES1-specific antibodies and ID1mRNA probe (magnification:×200). (C) Serial sections of human colon tumours stained with HES1-specific
antibody and ID1 mRNA probe showing presence and co-localization (Cancer 1) or differential expression (Cancer 2) of Notch and BMP
pathway target genes, respectively, in CRCs. These are representative images from analysis of 105 paraffin-embedded tumours. SEM,
standard error of the mean.
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Figure 4. Variable BMP signalling in different CRC molecular subtypes. (A) Left: relative BMP2 and BMP4 ligand expression in TCGA CRC
samples as compared with normal colonic tissues. CRC patients were divided into those having canonical (n= 149), MSI (n= 110) and
mesenchymal (n= 78) tumours. Values are represented as log2 fold change± standard error of the mean (SEM). P values were calculated
with ANOVA. Right: representative images of BMP2 and BMP4 mRNA in situ hybridization showing downregulation or upregulation of
ligands, respectively, in dysplastic versus normal human colonic tissue. (B) Relative BMPR1A, BMPR1B and BMPRII mRNA expression in
CRC samples as compared with normal colonic tissues. Values represent log2 fold change± SEM. P values were calculated with ANOVA.
(C) Relative SMAD1, SMAD4 and SMAD5 mRNA expression in CRC samples as compared with normal colonic tissues. Values represent log2
fold change± SEM. P values were calculated with ANOVA. (D) Normalized enrichment scores on TCGA CRC subtypes obtained by use of an
HCEC-generated BMP signature (281 genes) as an a priori gene set. P values were generated with Kolmogorov–Smirnov statistics. (E) Gene
set enrichment plots created by the use of a BMP signalling signature (281 genes) on two independent CRC datasets and a panel of CRC
cell lines, comparing mesenchymal with canonical subtypes. P values were generated with Kolmogorov–Smirnov statistics.
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mesenchymal tumours only (Figure 5A). We postulated
that BMP–Notch interaction can induce EMT in intesti-
nal epithelial cells, and that this phenotype is promoted
by the mesenchymal tumour microenvironment. To test
this, we used reverse transcription quantitative PCR, and
found a significant increase in expression of the EMT
transcription factor genes SNAI1 and SLUG in response
to BMP4 stimulation of HCECs (supplementary mate-
rial, Figure S3A). No effect was seen on ZEB1 expres-
sion (data not shown). The effect on SNAI1 induction
was abrogated by disrupting the intracellular BMP and
Notch pathways independently, by siRNA knockdown
of SMAD5 and HES1, respectively, but was unaffected
by HEY1 knockdown, suggesting that SNAI1 is down-
stream of HES1 alone in BMP–Notch crosstalk (sup-
plementary material, Figure S3B). Consistent with our
previous findings, SMAD1 knockdown resulted in
increased SNAI1 expression, indicating differential reg-
ulation of the BMP–Notch pathway interaction by the
different intracellular SMAD proteins (supplementary
material, Figure S3B). BMP4 stimulation induced an
EMT phenotype in HCECs, with increased expression
of vimentin protein and dynamic remodelling of the
actin cytoskeleton, as seen by assembly of F-actin
filaments into stress fibres, a phenomenon associated
with migratory cells [38]. Induction of this cellular
phenotype was independently abrogated by siRNA
disruption of mediating BMP and Notch signalling
components (Figure 5B).
To functionally assess the EMT phenotype, we
used cell migration assays to demonstrate a significant
increase in HCEC motility following BMP4 stimula-
tion (Figure 5D). Given the reported variable response
of individual cancer cell lines to BMP stimulation
[8,14–16], we attempted to predict the migratory
capacity of individual cancer cell lines before testing
the effect of BMP4. By generating individual cell line
EMT molecular signature scores, we could demon-
strate considerable heterogeneity of cell line EMT
gene signature expression, both within and between
groups from different tumour subtypes (Figure 5C). We
then assessed the effect of BMP4 stimulation on cell
migration in a panel of cancer cell lines with a predicted
migratory and non-migratory line from each tumour
subtype. This demonstrated that cancer cell lines with a
molecularly defined EMT phenotype are responsive to
BMP4-induced cell migration, irrespective of tumour
subtype gene signature (Figure 5D).
BMP, Notch and EMT gene signatures independently
identify patients with high-risk or low-risk CRC
To investigate the prognostic implications of a mech-
anistic link between BMP–Notch interaction and
induction of an EMT phenotype, we analysed associa-
tions between our BMP signalling signature (281 genes),
Notch target genes (83 genes) [28] and curated EMT
gene signature (84 genes) [27] with recurrence-free
survival in the TCGA dataset. The three gene signa-
tures are distinct, with <10% overlap between them
(supplementary material, Figure S3C), but, within
individual tumours in the TCGA cohort, there was
a significant correlation between expression levels
of BMP, Notch and EMT signatures (Fisher exact
test, p< 0.01; supplementary material, Figure S3D).
Importantly, patients with above-median expression
of each individual gene signature had significantly
shorter disease-free survival, with striking similarities
being seen between the Kaplan–Meier curves for the
different gene sets (BMP, p= 0.017; Notch, p= 0.017;
EMT, p= 0.015; Figure 5E–G). This demonstrates that
BMP, Notch and EMT gene signatures have similar
prognostic capabilities, and supports the involvement of
a BMP–Notch–EMT axis in the biological mechanisms
that contribute to poor prognosis in CRC.
Discussion
The BMP and Notch pathways are important, highly
conserved morphogenetic signalling pathways with
many convergent physiological functions in different
tissue systems. It was previously assumed that these
morphogens acted in parallel, independently regulating
transcription of their own target genes [39]; however,
more recently, synergistic or antagonist pathway inter-
action has been described in diverse tissue contexts,
including the mouse eye ciliary bodies [40], skeletal
muscle stem cells [41], and vascular endothelium [42].
In this study, we demonstrate, for the first time, that syn-
ergistic BMP and Notch signalling crosstalk also occurs
in human intestinal epithelial cells, and show that this
interaction can be regulated at an intracellular level, as
differential SMAD knockdown amplified or attenuated
the Notch pathway response to BMP stimulation. In
the homeostatic intestinal epithelial microenvironment,
morphogen signalling activity is necessarily strictly
regulated, with target gene activity being segregated to
different functional compartments of the crypt. BMP
and Notch co-activation is restricted to the upper part of
the human intestinal colonic crypt, and we hypothesize
that the physiological role of pathway crosstalk is to
translate the paracrine effect of secreted BMP ligands
into cell-to-cell, binary cell fate decisions through Notch
signalling, inducing terminal differentiation of cells as
they exit the transit-amplifying zone. Further in vivo
experiments will be required to confirm this (Figure 6).
In cancer, signalling dysregulation disrupts the finely
controlled morphogen balance and pathway segrega-
tion. Genetic context and differential expression of BMP
ligands, receptors, intracellular signalling proteins and
antagonists in human cancers and CRC cell lines has
led to confusion over the functional role and therapeu-
tic potential of BMP signalling. In this study, we used
normal explant-derived intestinal epithelial cells to gen-
erate a functional signature that characterizes BMP sig-
nalling. We used this to demonstrate variably active
BMP signalling across different CRC subtypes and cell
lines. Consistent with an anti-proliferative homeostatic
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Figure 5. BMP–Notch interaction induces an EMT phenotype. (A) Normalized enrichment scores on TCGA CRC subtypes according to Notch
and EMT signatures. P values were generated with Kolmogorov–Smirnov statistics. (B) Representative images of HCECs after 48 h of
SMAD5 or HES1 knockdown and after 24 h of BMP4 treatment, stained for vimentin or F-actin respectively. (C) Heterogeneity of EMT gene
set enrichment analysis score in CRC lines, both within and between different tumour subtypes. (D) Cell migration ratio (cell migration
after/before BMP4 stimulation) in a panel of predicted migratory and non-migratory cancer cell lines. (E–G) Kaplan–Meier plots displaying
recurrence-free survival (RFS) over time in all AJCC stages in the TCGA dataset. Log-rank test P value compares RFS over time for patients
grouped by KNN clustering according to BMP signature (E), Notch signature (F), and EMT signature (G) (blue is below median expression
levels of genes; red is above median expression levels).
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Figure 6. Model of BMP–Notch interaction in intestinal homeostasis and CRC disease subtypes. In intestinal homeostasis, the BMP and
Notch pathways are partially segregated. In the stem/progenitor zone at the base of the crypt, Notch signalling regulates intestinal
stem cells and promotes progenitor cell division. Specific co-localization of BMP and Notch signalling in cells emerging from the
transit-amplifying zone inhibits cell proliferation and promotes differentiation. In canonical tumours, loss of canonical BMP pathway
constituents downregulates BMP signalling, promoting cell proliferation. In mesenchymal tumours, impaired pathway segregation, loss
of SMAD1 and retention of SMAD5 enhance BMP–Notch interaction. In this model, BMP and Notch pathways act synergistically via
a γ-secretase-independent mechanism to promote an EMT phenotype, which we postulate is promoted by the mesenchymal tumour
microenvironment.
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role, BMP signalling is actively downregulated in the
majority of CRCs, but is paradoxically conserved in
poor-prognosis, mesenchymal tumours, where it acts
through Notch signalling to promote an EMT phenotype
(Figure 6). This demonstration of BMP signalling het-
erogeneity across different cancer subtypes and cell lines
may help to account for previous in vitro experimen-
tal inconsistencies [12,13,15–17]. Part of this variability
may be explained by retained expression of SMAD5,
which is the key intracellular mediator between the BMP
and Notch pathways, in the intestinal epithelium in mes-
enchymal tumours.
Like any investigation of human cell biology, this
study has its limitations. Our experimental model
required the use of a human cell line derived from a
normal adult intestinal explant. These cells are diploid
and have intact BMP and Notch signalling components,
but have been immortalized by expression of cyclin
dependent kinase 4 (CDK4) and catalytic component
of human telomerase (hTERT) [21]. Primary human
intestinal organoids were considered, but are dependent
on Noggin supplementation and are unable to tolerate
BMP ligand stimulation, which is cytostatic and induces
organoid collapse. There is a risk of generating artefac-
tual results from any in vitro assessment of signalling
pathways that are normally dependent on intercompart-
mental cellular interaction; however, the use of a normal
explant-derived line over CRC cell lines to assess BMP
signalling is justified by the recently demonstrated
influence of genetic mutation on BMP pathway activity
[18,19]. Furthermore, we have generated a clinically
relevant BMP signalling signature that has prognostic
implications in human CRC.
Our increasing understanding of the dysregulated
molecular signalling pathways in cancer has provided
a platform for the development of targeted therapies.
The development of BMP-targeted agents has been
hindered by confusion over the biological role of the
pathway in cancer [43]. Dysregulated Notch signalling
has been implicated in many cancers, where it has
a tumour-initiating [44], tumour-promoting or tumour
suppressor [45] function, depending on cellular con-
text and interactions with other pathways. In CRC,
increased expression of Notch pathway constituents has
been demonstrated in mouse intestinal tumour mod-
els [46], human cell lines [47], and some intestinal
tumours [48]. Furthermore, pharmacological inhibition
of the canonical Notch signal with GSIs prompted
secretory differentiation of proliferative adenoma cells
and a 50% reduction in ApcMin mouse tumour burden
[46]. GSIs have been proposed as a potential therapy
for colon cancer [49], and have undergone numerous
phase 1 combination chemotherapy trials in advanced
solid tumours [50,51]. Our work shows that the inhi-
bition of canonical Notch signalling in mesenchymal
CRCs is unlikely to be effective, as it will not prevent
direct Notch activation by BMP signalling, which acts
through a γ-secretase-independent mechanism. Differ-
ential therapeutic targeting of CRC based on molec-
ular subtype is an exciting prospect; however, further
research is required to understand the cellular mech-
anisms that underpin the variable biology of different
CRC types. This study, identifying a synergistic interac-
tion between two potentially targetable signalling path-
ways in aggressive CRCs, highlights the requirement for
multiple therapeutic agents to address the complex sig-
nalling derangement in CRC.
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